Reduced Thrombosis in Klkb1-/- Mice is Mediated by Increased Mas Receptor, Prostacyclin, Sirt1, and KLF4 and Decreased Tissue Factor

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2014 Oct 24

PMID 25339356

Citations 52

Authors

Evi X Stavrou

Chao Fang

Alona Merkulova

Omar Alhalabi

Nadja Grobe

Silvio Antoniak

Nigel Mackman

Alvin H Schmaier

Affiliations

Soon will be listed here.

Abstract

The precise mechanism for reduced thrombosis in prekallikrein null mice (Klkb1(-/-)) is unknown. Klkb1(-/-) mice have delayed carotid artery occlusion times on the rose bengal and ferric chloride thrombosis models. Klkb1(-/-) plasmas have long-activated partial thromboplastin times and defective contact activation-induced thrombin generation that partially corrects upon prolonged incubation. However, in contact activation-induced pulmonary thromboembolism by collagen/epinephrine or long-chain polyphosphate, Klkb1(-/-) mice, unlike F12(-/-) mice, do not have survival advantage. Klkb1(-/-) mice have reduced plasma BK levels and renal B2R mRNA. They also have increased expression of the renal receptor Mas and plasma prostacyclin. Increased prostacyclin is associated with elevated aortic vasculoprotective transcription factors Sirt1 and KLF4. Treatment of Klkb1(-/-) mice with the Mas antagonist A-779, COX-2 inhibitor nimesulide, or Sirt1 inhibitor splitomicin lowers plasma prostacyclin and normalizes arterial thrombosis times. Treatment of normal mice with the Mas agonist AVE0991 reduces thrombosis. Klkb1(-/-) mice have reduced aortic tissue factor (TF) mRNA, antigen, and activity. In sum, Klkb1(-/-) mice have a novel mechanism for thrombosis protection in addition to reduced contact activation. This pathway arises when bradykinin delivery to vasculature is compromised and mediated by increased receptor Mas, prostacyclin, Sirt1, and KLF4, leading to reduced vascular TF.

Citing Articles

Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis.

Lv K, Chen S, Xu X, Chiu J, Wang H, Han Y Nat Commun. 2024; 15(1):3129.

PMID: 38605050 PMC: 11009332. DOI: 10.1038/s41467-024-47493-0.

Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood.

Wan J, Dhrolia S, Kasthuri R, Prokopenko Y, Ilich A, Saha P Blood Adv. 2024; 8(12):3045-3057.

PMID: 38593231 PMC: 11215197. DOI: 10.1182/bloodadvances.2024012613.

A Multifunctional Therapeutic Strategy Using P7C3 as A Countermeasure Against Bone Loss and Fragility in An Ovariectomized Rat Model of Postmenopausal Osteoporosis.

Wei F, Hughes M, Omer M, Ngo C, Pugazhendhi A, Kolanthai E Adv Sci (Weinh). 2024; 11(21):e2308698.

PMID: 38477537 PMC: 11151083. DOI: 10.1002/advs.202308698.

Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond.

Motta G, Juliano L, Chagas J Front Physiol. 2023; 14:1188816.

PMID: 37711466 PMC: 10499198. DOI: 10.3389/fphys.2023.1188816.

Comparative Thrombin Generation in Animal Plasma: Sensitivity to Human Factor XIa and Tissue Factor.

Liang Y, Tarandovskiy I, Surov S, Ovanesov M Int J Mol Sci. 2023; 24(16).

PMID: 37629101 PMC: 10454801. DOI: 10.3390/ijms241612920.

References

Day S, Reeve J, Pedersen B, Farris D, Myers D, Im M . Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2004; 105(1):192-8. DOI: 10.1182/blood-2004-06-2225. View

Zhou G, Hamik A, Nayak L, Tian H, Shi H, Lu Y . Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J Clin Invest. 2012; 122(12):4727-31. PMC: 3533563. DOI: 10.1172/JCI66056. View

Munoz C . Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradative pathways. J Biol Chem. 1992; 267(1):303-9. View

Ghosh M, Wang H, Ai Y, Romeo E, Luyendyk J, Peters J . COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med. 2007; 204(9):2053-61. PMC: 2118704. DOI: 10.1084/jem.20070828. View

Muller F, Mutch N, Schenk W, Smith S, Esterl L, Spronk H . Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009; 139(6):1143-56. PMC: 2796262. DOI: 10.1016/j.cell.2009.11.001. View

Merkulov S, Zhang W, Komar A, Schmaier A, Barnes E, Zhou Y . Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2007; 111(3):1274-81. PMC: 2214772. DOI: 10.1182/blood-2007-06-092338. View

Fang C, Stavrou E, Schmaier A, Grobe N, Morris M, Chen A . Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood. 2013; 121(15):3023-32. PMC: 3624945. DOI: 10.1182/blood-2012-09-459156. View

Davie E, Ratnoff O . WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. Science. 1964; 145(3638):1310-2. DOI: 10.1126/science.145.3638.1310. View

Abildgaard C, Harrison J . Fletcher factor deficiency: family study and detection. Blood. 1974; 43(5):641-4. View

10.

Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G . Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation. 2010; 121(13):1510-7. DOI: 10.1161/CIRCULATIONAHA.109.924761. View

11.

Colman R, Mattler L, Sherry S . Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest. 1969; 48(1):11-22. PMC: 322187. DOI: 10.1172/JCI105959. View

12.

Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Rojkjaer R, Schmaier A . Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol. 2001; 280(4):H1821-9. DOI: 10.1152/ajpheart.2001.280.4.H1821. View

13.

Bjorkqvist J, Sala-Cunill A, Renne T . Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost. 2013; 109(3):368-74. DOI: 10.1160/TH12-08-0549. View

14.

Fraga-Silva R, Sorg B, Wankhede M, DeDeugd C, Jun J, Baker M . ACE2 activation promotes antithrombotic activity. Mol Med. 2010; 16(5-6):210-5. PMC: 2811560. DOI: 10.2119/molmed.2009.00160. View

15.

Matute-Bello G, Downey G, Moore B, Groshong S, Matthay M, Slutsky A . An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol. 2011; 44(5):725-38. PMC: 7328339. DOI: 10.1165/rcmb.2009-0210ST. View

16.

Han E, MacFarlane R, Mulligan A, Scafidi J, Davis 3rd A . Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002; 109(8):1057-63. PMC: 150945. DOI: 10.1172/JCI14211. View

17.

Espana F, Ratnoff O . The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents. J Lab Clin Med. 1983; 102(4):487-99. View

18.

Yeung F, Hoberg J, Ramsey C, Keller M, Jones D, Frye R . Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23(12):2369-80. PMC: 423286. DOI: 10.1038/sj.emboj.7600244. View

19.

Fraga-Silva R, Pinheiro S, Goncalves A, Alenina N, Bader M, Santos R . The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med. 2007; 14(1-2):28-35. PMC: 2078558. DOI: 10.2119/2007-00073.Fraga-Silva. View

20.

Hasan A, Amenta S, Schmaier A . Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation. 1996; 94(3):517-28. DOI: 10.1161/01.cir.94.3.517. View